Independence of progesterone-induced facilitation and inhibition of lordosis behavior in ovariectomized guinea pigs

In ovariectomized Hartley guinea pigs, 15 μg progesterone was shown to facilitate lordosis in 48% of animals when administered 36 hr after a 3.3 μg injection of estradiol benzoate. This dose of progesterone also inhibited lordosis behavior in 65% of animals administered an additional 0.6 mg progesterone at 60 hr. Significant inhibition of lordosis response to the 0.6 mg progesterone existed among animals in which lordosis was not facilitated by the initial 15 μg dose of progesterone. These results show that progesterone-induced inhibition can occur without prior facilitation of lordosis as tested by the manual stimulation technique.     

The influence of estradiol-17β dipropionate-progesterone ratios on uterine glycogen in the rat

Ovariectomized Holtzman rats were injected subcutaneously for three consecutive days with either oil, 1 μg of estradiol-17β dipropionate or 1 μg of estrogen plus 1, 5, 10 or 15 mg of progesterone. The animals were killed 24 hr after the last injection and uterine glycogen was determined. The estrogen increased uterine glycogen (both total and concentration) markedly over the control values, while all doses of progesterone given with estrogen suppressed the estrogen-induced total glycogen, but not the glycogen concentration. No dose of progesterone was more effective than another in altering the estrogen response. These data indicate that the E/P ratio is not as critical in evaluating uterine glycogen after three concurrent injections as it is after a single concurrent injection of the hormones.     

Dose-response of female llamas to ovulation-inducing factor from seminal plasma

The present study was designed to determine if the dose of purified ovulation-inducing factor (OIF) from llama seminal plasma required to provoke an ovulatory response is physiologically relevant in terms of the proportion present in a normal ejaculate and to test the hypothesis that corpus luteum (CL) form and function are affected by OIF in a dose-dependent manner. Female llamas were assigned randomly to five groups (n = 10 per group) and given a single i.m. dose of 500, 250, 125, or 60 μg of purified OIF (representative of the amount present in 1/25th to 1/200th of a normal ejaculate) or 1 ml of PBS (control). Ovulation and CL development were monitored by transrectal ultrasonography. Blood samples were taken to measure plasma progesterone concentrations and to determine changes in plasma concentrations of luteinizing hormone (LH). The high dose of OIF (500 μg) was associated with the highest incidence of ovulation (P < 0.05), the greatest maximum CL diameter (P < 0.05), and the largest day-to-day profiles of CL diameter (P < 0.05) and plasma progesterone concentrations (P < 0.01). A rise in plasma LH concentration was apparent in all llamas that ovulated and was most rapid and highest in the high-dose group (P < 0.01). The low dose of OIF (60 μg) was minimally effective for induction of ovulation and the least luteotrophic, as evidenced by the smallest maximum CL diameter and the smallest day-to-day profiles for CL diameter and plasma concentrations of progesterone and LH. Responses were intermediate for the middle-dose groups (125 and 250 μg). We conclude that OIF from llama seminal plasma has a dose-dependent effect on ovulation rate and CL form and function in llamas and that the biological effect of OIF is evident at physiologically relevant doses (i.e., as little as 1/100th of that present in an ejaculate).     

Estrogen induced changes in uterine sensitivity for the decidual cell reaction: Interactions between prostaglandin E2 and histamine or bradykinin

In rats receiving high doses of estrogen along with progesterone, the uterus is desensitized and does not respond to artificial stimuli with increased endometrial vascular permeability or decidualization. In addition, prostaglandin E₂ (PGE₂), the putative mediator of endometrial vascular permeability changes in sensitized uteri, is ineffective when given into the uterine lumen. The possibility that this inability of PGE₂ to increase endometrial vascular permeability may be related to the unavailability of hitamine of bradykinin was investigated. Rats were differentially sensitized for the decidual cell reaction by the daily injection of 2 mg progesterone with either 0.5 of 10 μg estrone for the 3 days preceding the unilateral intra-uterine injection of 50 μl phosphate buffered saline containing gelatin with or without 10 μg PGE₂ and with or without 1 mg histamine or 1 μg bradykinin. Prior to the intrauterine injection, all rats were treated with indomethacin to inhibit endogenous prostaglandin production. Endometrial vascular permeability changes were determined 8 h later by determining radioactivity levels in injected and non-injected uterine horns 15 min after the i.v. injection of ¹²⁵I-labelled bovine serum albumin. PGE₂ increased endometrial vascular permeability in rats receiving 0.5 μg estrone, but not in those receiving 10 μg. Histamine or bradykinin, alone or with PGE₂, did not affect endometrial vascular permeability in rats receiving either estrogen dose. The data suggest that the unresponsiveness of uteri from rats treated with high doses of estrogen is not simply due to the unavailability of bradykinin or histamine.     

Cervical mucus and oestrous behaviour responses to oestrogens in sheep: Progesterone-oestrogen relationships and role of progesterone pre-treatment

The final dose of progesterone (5, 10, 20 mg) and time to oestrogen injection relative to the final dose of progesterone (24–72 h) had no significant effect on the production of cervical mucus measured 24 h after the injection of 30 μg oestradiol benzoate (ODB). However, there were significant effects on the behavioural oestrous responses (time from injection of oestrogen to onset of oestrus and duration of oestrus). Time to onset of oestrus increased from 18 to 27.8 h with increasing dose of progesterone (P < 0.001) and decreased from 24.8 to 20 h with increasing time to oestrogen injection (P < 0.05). Conversely, the duration of oestrus decreased from 36.2 to 23.8 h with increasing dose of progesterone (P < 0.001) and increased from 29 to 39 h with increasing time to oestrogen injection (P < 0.01).Ovariectomized ewes became refractory to ODB as measured by the cervical mucus response after the fifth sequential daily injection of 20 μg oestradiol benzoate. Progesterone priming was not required to restore subsequent sensitivity to oestrogen treatment. However, there was a positive linear relationship between length of recovery period and level of response to subsequent treatment.It was concluded that: (1) progesterone pre-treatment or priming is not necessary in the cervical mucus bioassay in ovariectomized ewes; and (2) a period of 8–16 days is needed between assays for normal sensitivity to be regained.     

Doses of prostaglandin analogue “cloprostenol” by intravulvo-submucosal (IVSM) injections effective for the induction of oestrus in goats

In order to ensure that all goats responded equally to varying dosages of cloprostenol (Clo.) without considering the stage of the oestrous cycle, 25 goats were injected (treatment A) between days 11 and 14 of the oestrous cycle with 125 μg Clo./goat intramuscularly (IM). At the time of the second injection, given 11 days later, five different treatments (treatment B), consisting of 125 μg Clo.IM, 125 μg Clo. IVSM, 62.5 μg Clo. IVSM, 31.25 μg Clo. IVSM and saline IM, were given to groups 1, 2, 3, 4 and 5, respectively. Oestrus was monitored by teaser bucks. Blood samples taken at the time of treatment B and daily for 6 days thereafter were assayed for progesterone to confirm that luteolysis had occurred as expected. All goats in groups 1, 2 and 3, and one out of five in group 4 exhibited oestrus within 68 h of treatment B. Serum progesterone levels exhibited values below 1 ng/ml within 24 h of treatment B in groups 1, 2 and 3 and decreased to nadir levels within 48 h of treatment B. Lack of luteolysis in goats of groups 4 and 5, as shown by progesterone concentrations, was the reason for failure of synchronization in these groups. It is concluded that a small dose of cloprostenol given by intravulvo-submucosa injection is effective in inducing oestrus in dioestrous cycling goats.     

Luteal function in sheep injected with prostaglandin F2α directly into the corpus luteum

Groups of ewes received either saline or prostaglandin F_2α (PGF_2α) as an injection directly into the corpus luteum. Changes in circulating progesterone levels were measured as well as subsequent histological examination of the corpora lutea. Saline, or PGF_2α given at the two lower doses (60 and 120 μg respectively), failed to suppress progesterone levels permanently, or to induce degenerative changes in the corpora lutea. Treatment with a higher dose of PGF_2α (240 μg) was followed by a marked elevation in progesterone levels. These results are discussed in relation to reported effects of PGF_2α arriving at the ovary via the arterial circulation.     

Follicle-stimulating hormone stimulated differentiation and progesterone production of bovine granulosa cells in culture

Progesterone production of granulosa cells cultured in vitro is stimulated and cell differentiation increased, by follicle-stimulating hormone (FSH). This study examined whether the increased progesterone production observed when bovine granulosa cells are cultured occurs because (1) progesterone production by undifferentiated and/or differentiated cells is increased or (2) the differentiation of granulosa cells is stimulated. Viable bovine granulosa cells (2−3×10⁵) from follicles 5–8 mm in diameter were cultured in the presence of 0, 1, 10 and 100 μu FSH (1 μu ≡ 1 μg NIH-FSH-S1) for 6 days at 37°C in a humidified atmosphere of 5% CO₂ in air in 1 ml of a 1:1 mixture of Dulbecco's modified Eagle medium: Ham's F10 medium supplemented with 365 μg ml⁻¹ l-glutamine, 100 U ml⁻¹ penicillin and 100 μg ml⁻¹ streptomycin. Progesterone production, total DNA and protein, and cell diameter were determined sequentially over the culture period. The increases in progesterone production (ng μg⁻¹ DNA per 24 h), cytoplasmic:nuclear ratio (μg protein μg⁻¹ DNA) and cell diameter (μm) over 6 days culture indicated that granulosa cells underwent differentiation in the presence of FSH. Progesterone production of undifferentiated granulosa cells (diameter 14 μm or less) was stimulated by FSH (P < 0.01) in a dose dependent manner (1.0±0.2, 2.9±0.3, 3.7±0.3 and 4.9±0.4 ng μg⁻¹ DNA per 24 h for 0, 1, 10 and 100 μu ml⁻¹ FSH respectively) but remained constant within dose (P > 0.05) during a 6 day culture period. FSH stimulated (P < 0.05) the rate of granulosa cell differentiation (10±3%, 53±13%, 74±21% and 82±10% differentiating cells per well for 0 μu, 1 μu, 10 μu and 100 μu ml⁻¹ FSH respectively) but did not stimulate (P > 0.05) progesterone production by differentiating granulosa cells (8.7±0.5 ng μg⁻¹ DNA per 24 h). In conclusion, the increase in progesterone production of FSH-stimulated granulosa cells cultured in vitro appears to be mainly due to an increase in the number of differentiating cells with a constant rather than an increasing progesterone production per cell.     

Progesterone inhibition of estrogen-induced maternal behavior in hysterectomized-ovariectomized virgin rats.

Hysterectomized-ovariectomized virgin rats were tested for maternal behavior following treatment with 100 μg/kg EB immediately at surgery and either oil, 0.5 or 5.0 mg progesterone either 0, 24 or 44 hr following surgery. Stimulus pups were presented 48 hr postoperatively which is counted as Day 0 of testing. EB + oil-treated females displayed short-latency maternal behavior beginning on Day 0. The injection of 5.0 mg progesterone at 0, 24, or 44 hr significantly inhibited the onset of maternal care while the effect of the lower dose of progesterone depended upon the timing of its administration in relation to that of EB. At a dose of 0.5 mg, progesterone given 24 hr following EB, inhibited the appearance of maternal behavior but had no effect given at 44 hr, and resulted in only a partial delay when given at the same time as the EB. Possible mechanisms by which progesterone interfered with the display of maternal behavior were discussed.     

Dose-response and time-response relationships between progesterone and the display of patterns of receptive and proceptive behavior in the female rat

The relationship between administration of progesterone and the display of patterns of receptive (response to the male) and preceptive (female initiated) sexual behavior was examined in ovariectomized, estrogen-primed female rats in a “restrained male” test situation. It was found that the degree of receptivity and proceptivity displayed was directly proportional to progesterone dose and time from progesterone injection (up to 4.5 hr). Higher progesterone doses and longer period of time from progesterone injection (up to 4.5 hr) were both associated with shorter latencies to return to the male following intromission and ejaculation. Receptivity could be induced with estrogen alone but progesterone was required for the display of proceptivity and higher doses of progesterone were needed to effect increases in proceptivity relative to receptivity. Proceptive behavior also occurred in a narrower time range than did receptive behavior. Receptivity alone is characterized as the lowest degree, and receptivity plus proceptivity as the highest degree, of expression of the total behavior pattern of the estrous female rat. Receptivity and proceptivity together constitute a continuum of estrous responsiveness. Increasing the progesterone dose from 0 to 200 μg, and increasing the latency from progesterone injection from 0 to 4.5 hr, were associated with increasing degree of expression of the total behavioral continuum.     

The influence of dose and duration of estrogen treatment on corpus luteum regression in ewes

Estrogen-induced regression of corpora lutea (CL) was studied in two experiments using 190 cycling ewes. In an experiment with a 3 × 5 factorial design, the minimum amounts of estradiol-17β (E₂), estrone (E₁) and diethylstilbestrol (DES) required to induce CL regression by intramuscular injection were determined. Injections of either 0, 100, 250, 500 or 1,000 μg of each estrogen were administered on days 10 and 11 of the estrous cycle. Each dose level of estrogen significantly reduced CL weight by day 14, and the 250 μg and higher dosages significantly reduced CL progesterone content. The luteolytic potencies of the three estrogens did not differ significantly.In the second experiment, E₂ was infused into the jugular vein of ewes on day 10 of the estrous cycle at a rate of 1.3 to 41.6 μg/hr for either 12, 24, or 48 hours. Infusion of E₂ for 12 hr did not significantly reduce either the weight or progesterone content of CL, even when as much as 500 μg of E₂ (41.6 μg/hr) was administered. In contrast, a total of 62 μg of E₂ infused over a 24-hr period (2.6 μg/hr) significantly reduced CL weight and CL progesterone. Therefore, CL regression induced by infusion of E₂ on day 10 of the cycle was dependent on the duration of the E₂ treatment as well as on the amount of E₂ infused.     

The effects of estrogen and progesterone on female rat proceptive behavior

The relative importance of estrogen (EB) and progesterone (P) in stimulating proceptivity in ovariectomized female rats was studied. Proceptive behavior was measured quantitatively, providing a clear measure of response to experimental manipulation. When rats were tested biweekly after daily treatment with 0.4 μg/100 g body wt EB for 4 days, they showed maximal lordosis but low levels of proceptive behavior by the second test. Additional EB (3.0 μg/100 g body wt daily) failed to stimulate additional proceptivity. A graded increase in proceptive behavior resulted from administration of increasing doses of P (50, 100, 500 μg and 1.0 mg) to animals receiving EB priming as described above. The level of “soliciting” was significantly higher than EB-only-treated rats when 500 μg or 1.0 mg P was given. Ovariectomized, adrenalectomized rats, primed with 2.5 μg/100 g body wt EB daily for 7 days and tested on Day 8, were significantly less proceptive than ovariectomized, sham-adrenalectomized rats with the same hormone treatment. Four hours after injection of 1.0 mg P, there was no difference in proceptive or receptive behavior between sham- and adrenalectomized rats. It was concluded that if an EB dose is sufficient to induce maximal receptivity, additional estrogen does not stimulate proceptivity; unlike previous studies, the present data are not consistent with a global effect of ovarian steroids on both components of female behavior. Progesterone is more effective than estrogen in stimulating proceptive behavior, although proceptivity is not absolutely dependent on progesterone for expression. Proceptivity in EB-only-treated rats appears to be facilitated by adrenal P.     

Effects of septal lesions on behavioral sensitivity of female rats to gonadal hormones

Spayed female rats were given bilateral septal lesions or a sham operation and 3 wk later tested for hormone-induced female sexual behavior. When primed with 0.5, 1.0, or 2.0 μg of estradiol benzoate (EB) per day for 3 days and tested for lordosis behavior on the fourth day, animals with septal lesions showed a positive dose-related increase in mean lordosis quotient (LQ), whereas control animals showed a low mean LQ for all doses of EB. After priming with a low dose of EB (0.5 μg/day for 3 days), progesterone administration prior to behavior testing on day 4 produced a comparable facilitation in LQ for both septal-lesioned and sham-operated animals. When treated for 3 days with either 50 or 150 μg of testosterone propionate (TP) and given progesterone prior to behavior testing on day 4, female rats with septal lesions showed a higher mean LQ than sham-operated rats. Thus, septal lesions increase the behavioral sensitivity of female rats to both EB and TP as measured by female sexual behavior, but do not appear to alter the responsiveness of animals to progesterone.     

Menstrual induction with the PGF2α-analogue ICI 81008

“Menstrual Induction” (MI) has been studied in 79 volunteers, using the therapeutic principle of “PG-Impact”. The PGF2α analogue: ICI 81008 was administered under strictly aseptic precautions into the uterine cavity during the 4th week of pregnancy. The treatment catheter (inserted through the cervical canal) delivered a single dose of only 100–200 μg ICI 81008 during the pilot study with this new drug. When it was established that the side effects were acceptable, this moderately effective dose was increased at first to 200–300 μg and eventually to 400 μg.At the 400 μg dose level, 29 (76%) of the 38 study patients had complete and 8 (21%) incomplete abortions, while 1 (3%) failed to bleed. Those 9 women who had incomplete abortions or failed to abort were curetted. In comparison with PGF2α (428 cases) and PGE₂ (114 cases), ICI 81008 (38 cases at the 400 μg level) provoked lesser side effects, excepting the transient increase in blood pressure.All patients (whose intrauterine pressure was measured) responded to the ICI 81008-impact with rapidly developing high level uterine contracture. Plasma progesterone decreased significantly if treatment was successful and insignificantly in cases of treatment failure. In current studies, the efficacy of the vaginal delivery system of ICI 81008 is examined.     

Effect of estradiol-17β on the conversion of pregnenolone to progesterone in human term placenta incubated in vitro

The effect of different doses of estradiol-17β (E₂) on the netabolic pregnenolone to progesterone pathway in fragments of human term placenta incubated $\text{in vitro}$ was studied. Doses considered as being physiological of 0.09 and 0.9 μM had a stimulatory effect on the conversion (p < 0.008 to 0.0l6). However, a supraphysiological dose of 45 μM showed an inhibitory activity related to the maximal stimulation (p < 0.03). A dose of 0.9 μM E₂ favoured the accumulation of (³H)-progesterone in the tissue (p < 0.05). These results suggest that E₂ may regulate the synthesis of progesterone in human term placenta.     

Hormonal basis of hysterectomy-induced maternal behavior during pregnancy in the rat.

Hysterectomy during the last half of pregnancy (i.e., Day 10–19) induces a rapid onset of maternal behavior; ovariectomy in addition to hysterectomy, prevents this effect. Estradiol and progesterone were tested for their ability to restore short-latency maternal behavior in hysterectomized-ovariectomized (HO) females operated on the 10th, 13th, 16th and 19th days of pregnancy. A single injection of either 20 μg/kg or 100 μg/kg estradiol benzoate (EB) immediately following HO either alone or followed by 0.5 mg progesterone (P) 44 hr later restored short-latency maternal behavior similar to that observed following hysterectomy only. The lower dose of EB was found to be equally effective at all stages of pregnancy and P was unnecessary to induce maternal behavior. The effectiveness of EB in inducing maternal behavior was discussed in relation to the hormonal changes which follow hysterectomy during pregnancy and to those which are associated with the normal onset of maternal behavior around parturition.     

Hormone induced lordosis and its relation to masculine sexual activity in male rats

Intact and castrated male rats were injected with a single dose of estrogen (75 μg), followed by progesterone (1 mg) or by oil. Intact males showed higher lordosis quotients as compared to castrated males. Progesterone facilitated lordosis behavior in castrated as well as in intact males. An estrogen-progesterone treated group of sexually inactive male rats and of sexually exhausted males showed lower levels of lordosis as compared to the intact sexually active males.     

The display of sexual behaviors by female rats administered ICI 182,780

ICI 182,780 (ICI) is a pure antiestrogen that when administered systemically does not cross the blood-brain barrier, thus its actions are limited to the periphery. Four experiments were conducted to test the effects of ICI on the display of sexual behaviors in ovariectomized rats. Experiment 1 examined the effects of three doses of ICI (250, 500, and 750 μg/rat) on sexual receptivity and paced mating behavior in rats primed with estradiol benzoate (EB) in combination with progesterone (P). Experiments 2 and 3 compared the display of sexual behaviors in rats primed with EB+P or EB alone and administered either 250 μg ICI (Experiment 2) or 500 μg ICI (Experiment 3). Experiment 4 tested the effects of ICI (250 and 500 μg) on the expression of estrogen-induced progestin receptors in the uterus. ICI did not affect the display of sexual receptivity in any experiment. In rats primed with EB+P, paced mating behavior was altered by the 500 and 750 μg, but not the 250 μg, doses of ICI. The lowest (250 μg) dose of ICI did alter paced mating behavior in rats primed with EB alone. The effects of ICI on paced mating behavior were manifested by a substantial lengthening of contact-return latencies following intromissions and ejaculations. The percentage of exits were not affected by ICI. Estrogen stimulation of uterine weight and induction of uterine progestin receptors was suppressed by ICI (250 and 500 μg). ICI effects on paced mating behavior in hormone-primed female rats are likely to reflect antiestrogenic actions in the periphery, including interference with the estrogen induction of progestin receptors.     

Antagonism of the actions of estrogens,androgens and progesterone by anordrin (2α,17α-diethynyl-A-nor-5α-androstane-2β, 17β-diol dipropionate)

Anordrin, an antifertility agent that is an antiestrogen with weak estrogenic activity, has been studied to further characterize its hormonal activities. A dose of 2.0 μg/mouse·day for 7 days did not increase the uterine content of protein, but it did inhibit to a small extent the effect of administered estradiol-17β on uterine protein content and more significantly the effect of estradiol-17β on the uterine content of progesterone receptors. Anordrin also decreased serum corticosteroid-binding globulin levels. Administration of an average daily dose of 160 μg/day of anordrin to intact male mice had no effect on weights of kidney, testis, or seminal vesicle after 10 days, but seminal vesicle weight was significantly decreased after 30 days at a slightly lower dose. Similarly, anordrin inhibited the increase in seminal vesicle weight induced by testosterone propionate treatment of castrated mice. In female mice anordrin failed to maintain deciduomata and blocked the ability of progesterone (2.0 mg/mouse·day) to do so. However, anordrin did not compete with the androgen [³H]R1881 for binding in kidney cytosol or with the progestin [³H]R5020 for uterine receptor sites. Anordrin also did not compete with [³H]corticosterone for binding to serum proteins.     

The inhibition of steroid-induced sexual behavior by intrahypothalamic actinomycin-D

Lordosis behavior can be elicited in the ovariectomized rat after treatment with estradiol benzoate (EB) and progesterone (P) injections, but the EB must act for an extended period before P can facilitate this behavior. The possibility that this action of EB involves the stimulation of RNA or protein synthesis was tested by implanting actinomycin D (Act-D) directly into the preoptic area, one probable site of estrogen action. A total dose of 0.18 μg Act-D in bilateral cocoa butter pellets significantly inhibited lordosis behavior when implanted 12 hr after the injection of 3 μg. but not 15 μg EB. Implantation of this dose of Act-D subcutaneously, or intrahypothalamically 32 hr after EB injection, was without effect. Act-D placed in the ventromedial hypothalamus also suppressed lordosis, but implants in the caudate nucleus were without effect. At the time of the behavioral tests the animals were in excellent condition as determined by calculation of a health score, and no physical lesions were evident at the site of the implants. However, it was impossible to test the reversibility of this suppression of lordosis behavior since the animals became ill and many died within 1–2 weeks of implantation. The present results are consistent with, but not proof of, the concept that RNA synthesis may be essential for steroidinduced sexual behavior.